Warning Letter — RonanRx, Inc. dba RonanRx
The FDA issued a Warning Letter to RonanRx, Inc. (dba RonanRx) on October 30, 2026, following an evaluation by the Center for Drug Evaluation and Research (CDER).
This affects RonanRx, Inc. and its operational management, specifically those overseeing drug evaluation and compliance at the cited location.
A Warning Letter from CDER signifies that the FDA has identified significant violations of regulatory requirements. While the specific nature of the violations is not detailed in the provided excerpt, such actions typically imply underlying issues with cGMP, labeling, or unapproved drug status, potentially leading to import alerts or seizure if not remediated.
The recipient should conduct a comprehensive internal audit of the cited facility to ensure compliance with CDER standards. Firms should prepare for a formal response to the FDA addressing all specific observations mentioned in the full Warning Letter text.
FDA Warning Letter issued to: RonanRx, Inc. dba RonanRx. 10/30/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ronanrx-inc-dba-ronanrx-737905-10302026
Open in openFDA / FDA.gov